Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIA632 in moderate to severe atopic dermatitis
NCT07220577Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Nov 2025
- Primary completion
- May 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of GIA632 in atopic dermatitis (AD), sponsored by Novartis. Started Nov 2025; status: active, not recruiting.
02
Drugs
GIA632
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07220577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07220577.